keyword
https://read.qxmd.com/read/38628650/different-therapeutic-approaches-in-melasma-advances-and-limitations
#1
REVIEW
Parisa Ghasemiyeh, Rahil Fazlinejad, Mohammad Reza Kiafar, Shiva Rasekh, Mohammad Mokhtarzadegan, Soliman Mohammadi-Samani
Melasma is a chronic hyperpigmentation skin disorder that is more common in the female gender. Although melasma is a multifactorial skin disorder, however, sun-exposure and genetic predisposition are considered as the main etiologic factors in melasma occurrence. Although numerous topical and systemic therapeutic agents and also non-pharmacologic procedural treatments have been considered in melasma management, however, the commonly available therapeutic options have several limitations including the lack of sufficient clinical effectiveness, risk of relapse, and high rate of unwanted adverse drug reactions...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38618759/supramolecular-salicylic-acid-combined-with-niacinamide-in-chloasma-a-randomized-controlled-trial
#2
JOURNAL ARTICLE
Ying Xiong, Xian Jiang, Wei Lai, Xinghua Gao, Yan You, Yongmei Huang, Xueli Li, Junling Zhang, Shiqin Tao, Jin Chen, Wei Zhang, Nan Yu, Nan Xu, Chunling Liu, Weihui Zeng, Shichao Lv, Gang Wang
BACKGROUND: No trial of supramolecular salicylic acid (SSA) for chloasma is available yet. OBJECTIVE: The purpose of this study was to assess the efficacy and safety of Bole DA 30% supramolecular salicylic acid (SSA) combined with 10% niacinamide in treating chloasma. METHODS: This multicenter (n=15), randomized, double-blind, parallel placebo-controlled trial randomized the subjects (1:1) to Bole DA 30% SSA or placebo. The primary endpoint was the effective rate after 16 weeks using the modified melasma area severity index (mMASI) [(pretreatment-posttreatment)/pretreatment×100%]...
April 15, 2024: Clinical and Experimental Dermatology
https://read.qxmd.com/read/38610881/advancements-in-laser-therapies-for-dermal-hyperpigmentation-in-skin-of-color-a-comprehensive-literature-review-and-experience-of-sequential-laser-treatments-in-a-cohort-of-122-indian-patients
#3
REVIEW
Suruchi Garg, Kanya Rani Vashisht, Diksha Garg, Bhavni Oberoi, Geeta Sharma
The heightened awareness of ethnic dermatology aligns with the growing prevalence of skin of color communities globally, where hyperpigmentation disorders pose a common dermatological challenge. Effectively addressing dermal pigmentation is challenging due to its resistance to conventional therapies and its association with impaired quality of life. This underscores the need for effective treatments and a thorough grasp of laser advancements. A relevant literature search spanning the last 7 years across the PubMed database reveals core studies, challenges, and the evolution of laser technologies tailored for various forms of congenital and acquired dermal hyperpigmentation in skin of color...
April 5, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38608837/newly-identified-peptide-nigrocin-oa27-inhibits-uvb-induced-melanin-production-via-the-mitf-tyr-pathway
#4
JOURNAL ARTICLE
Jiayi Li, Saige Yin, Ziqi Wei, Zhaoxun Xiao, Zijian Kang, Yutong Wu, Yubing Huang, Qiuye Jia, Ying Peng, Zeqiong Ru, Xiaohan Sun, Yuliu Yang, Qian Yang, Junyuan Wang, Chengxing Liu, Meifeng Yang, Ying Wang, Xinwang Yang
Melasma is a common skin disease induced by an increase in the content of melanin in the skin, which also causes serious physical and mental harm to patients. In this research, a novel peptide (Nigrocin-OA27) from Odorrana andersonii is shown to exert a whitening effect on C57 mice pigmentation model. The peptide also demonstrated non-toxic and antioxidant capacity, and can significantly reduce melanin content in B16 cells. Topical application effectively delivered Nigrocin-OA27 to skin's epidermal and dermal layers and exhibited significant preventive and whitening effects on the UVB-induced ear pigmentation model in C57 mice...
April 10, 2024: Peptides
https://read.qxmd.com/read/38592701/management-of-melasma-laser-and-other-therapies-review-study
#5
REVIEW
Badea Jiryis, Ohad Toledano, Emily Avitan-Hersh, Ziad Khamaysi
Melasma is a commonly occurring pigmented skin condition that can significantly affect one's appearance, described as symmetric hyperpigmentation that presents as irregular brown to gray-brown macules on various facial areas, such as the cheeks, forehead, nasal bridge, and upper lip, along with the mandible and upper arms. Due to its complex pathogenesis and recurrent nature, melasma management is challenging and the outcomes following treatment are not always deemed satisfactory. Solely treating hyperpigmentation may prove ineffective unless paired with regenerative techniques and photoprotection, since one of the main reasons for recurrence is sun exposure...
March 3, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38581222/topical-isoniazid-as-a-novel-treatment-for-melasma-a-randomized-double-blind-vehicle-controlled-clinical-trial
#6
JOURNAL ARTICLE
Najmeh Ahramiyanpour, Zahra Mahmoudi, Nazanin Zeinali Nezhad, Payam Khazaeli, Rezvan Amiri, Behrooz Kasraee
INTRODUCTION: Melasma is a chronic hyperpigmentation disorder, and its treatment poses a challenge to dermatologists due to its chronicity and resistance to conventional therapies. Oral isoniazid is used for the treatment of tuberculosis. One of us had previously showed that topical isoniazid exerts a strong depigmenting action in animal models. In this clinical trial, we assessed the therapeutic effect of topical isoniazid on melasma. METHODS: Twenty female patients suffering from epidermal melasma were enrolled and divided equally into two groups...
April 6, 2024: Journal of Cosmetic Dermatology
https://read.qxmd.com/read/38574769/comparative-long-term-efficacy-of-phenol-croton-oil-chemical-peels-for-persistent-melasma-at-varied-croton-tiglium-oil-concentrations
#7
JOURNAL ARTICLE
Mayra B C Maymone, Fatima N Mirza, Denise Steiner, Felipe Ribeiro, Marina Landau, Carolina Marçon, Tereza C Celidonio, Seaver L Soon, Carlos G Wambier
No abstract text is available yet for this article.
April 2, 2024: Journal of the American Academy of Dermatology
https://read.qxmd.com/read/38568090/a-novel-professional-use-synergistic-peel-technology-to-reduce-visible-hyperpigmentation-on-face-clinical-evidence-and-mechanistic-understanding-by-computational-biology-and-optical-biopsy
#8
JOURNAL ARTICLE
Vinay Bhardwaj, Marc Zachary Handler, Junhong Mao, Chloe Azadegan, Pritam K Panda, Hans Georg Breunig, Isabell Wenskus, Isabel Diaz, Karsten König
Topicals and chemical peels are the standard of care for management of facial hyperpigmentation. However, traditional therapies have come under recent scrutiny, such as topical hydroquinone (HQ) has some regulatory restrictions, and high concentration trichloroacetic acid (TCA) peel pose a risk in patients with skin of colour. The objective of our research was to identify, investigate and elucidate the mechanism of action of a novel TCA- and HQ-free professional-use chemical peel to manage common types of facial hyperpigmentation...
April 2024: Experimental Dermatology
https://read.qxmd.com/read/38564390/expanding-inclusivity-tranexamic-acid-for-the-treatment-of-melasma-in-males
#9
JOURNAL ARTICLE
Nicole E Chin, Andrea Hui Austin
No abstract text is available yet for this article.
April 1, 2024: Journal of Drugs in Dermatology: JDD
https://read.qxmd.com/read/38557458/validation-of-the-onychomycosis-severity-index-in-a-brazilian-population
#10
JOURNAL ARTICLE
Maria Claudia Carvas Passarelli Tirico, Luis Torezan
Onychomycosis is the most frequent nail disorder, but unfortunately, curative treatment is still a challenge, and commonly the infection recurs. A widely disseminated system to accurately assess and classify the severity of this disease, such as the MASI score for melasma or PASI for psoriasis, is lacking in the literature. In 2011, Carney et al. established and successfully validated the Onychomycosis Severity Index (OSI), proving it to be a simple and reproducible tool. To validate the Onychomycosis Severity Index in a Brazilian population...
February 1, 2024: European Journal of Dermatology: EJD
https://read.qxmd.com/read/38549597/the-use-of-tranexamic-acid-in-dermatology
#11
REVIEW
Klara Gaćina, Anđela Krstanović Ćosić
Tranexamic acid is a synthetic derivative of the amino acid lysine, an antifibrinolytic that is primarily used to reduce bleeding in surgery, trauma, and dental procedures. Its anti-inflammatory and anti-angiogenic properties, as well as its ability to suppress melanogenesis have enabled it to be used in dermatology in the treatment of skin conditions such as melasma, acne, post-inflammatory hyperpigmentation, rosacea and angioedema. Tranexamic acid can be used by various routes of administration including oral, topical and intradermal injection, and in combination with other treatment methods...
August 2023: Acta Clinica Croatica
https://read.qxmd.com/read/38549196/efficacy-and-tolerability-of-a-depigmenting-gel-serum-comprising-tranexamic-acid-niacinamide-4-butylresorcinol-phytic-acid-and-a-mixture-of-hydroxy-acids-that-targets-the-biological-processes-regulating-skin-melanogenesis
#12
JOURNAL ARTICLE
Marta Furmanczyk, Anthony Brown, Javier Bustos, Antonio R Fernández de Henestrosa, Carles Trullas, Corinne Granger, Eric Jourdan
BACKGROUND: The diverse causes of hyperpigmentation and complex nature of melanogenesis make it a challenge to manage. Current approaches either fail to deliver effective pigmentation control or have undesirable safety profiles that preclude their long-term use. AIMS: To evaluate the capacity of a cosmetic gel serum comprising tranexamic acid, niacinamide, 4-butylresorcinol, phytic acid, and a mixture of hydroxy acids that was designed to target the biological processes regulating skin melanogenesis to attenuate melanin production in vitro and reduce hyperpigmentation clinically...
March 28, 2024: Journal of Cosmetic Dermatology
https://read.qxmd.com/read/38545140/efficacy-and-safety-of-adjuvant-topical-application-of-botanicals-in-the-treatment-of-melasma-a-systematic-review-and-meta-analysis
#13
JOURNAL ARTICLE
Lin Guo, Yuanxin Zhang, Siqing Wu, Ming Bai, Shuo Tian, Mingsan Miao
OBJECTIVE: To systematically evaluate the efficacy and safety of topical application of botanical (TAB) adjuvants in the treatment of melasma and provide evidence-based medical evidence for their clinical application. METHODS: Medline, Web of Science, EMBASE, Cochrane Library, CNKI, VIP, Wanfang Data, and SinoMed, databases were searched to identify all randomized controlled clinical trials on TAB adjuvant treatment for melasma from inception to May 2023. The primary outcomes included clinical efficacy, adverse effects, recurrence rate, and melanin index...
March 30, 2024: Heliyon
https://read.qxmd.com/read/38539056/enhancing-tranexamic-acid-penetration-through-aqp-3-protein-triggering-via-zif-8-encapsulation-for-melasma-and-rosacea-therapy
#14
JOURNAL ARTICLE
Jie Tang, Yu Li, Xuefeng Hu, Wei Hua, Haoning Xu, Li Li, Fujian Xu
The systemic use of tranexamic acid (TA) as an oral drug could bring adverse reactions, while intradermal injection leads to pain and a risk of infection. Moreover, it is difficult for highly hydrophilic TA to penetrate the skin barrier that contains lots of hydrophobic lipid compounds, which poses enormous restrictions on its topical application. Current transdermal TA delivery strategies, are suffering from low drug load rates, plus its synthesis complexity, time-consumption etc., adding to the difficulty of TA topical application in clinical therapeutics...
March 27, 2024: Advanced Healthcare Materials
https://read.qxmd.com/read/38533362/comparison-of-the-efficacy-of-hydroquinone-cream-versus-hydroquinone-cream-plus-danggui-shaoyao-powder-in-the-treatment-of-melasma
#15
JOURNAL ARTICLE
Yuan-Yuan Cheng, Rui-Rui Peng, Hao Luo, Wei Zhao
INTRODUCTION: Melasma is an acquired hypermelanosis and occurs in areas exposed to sunlight. AIM: To investigate the effectiveness of Danggui Shaoyao powder (DSP) as a complementary drug in the treatment of melasma. MATERIAL AND METHODS: A total of 40 melasma patients over the age of 18 who met the inclusion criteria entered the study randomly in two DSP + Hydroquinone (DSP + H) and Hydroquinone (H) groups. RESULTS: At the beginning of the study, the average MASI score of the two groups of patients had no statistical difference (DSP + H: 15...
February 2024: Postȩpy Dermatologii i Alergologii
https://read.qxmd.com/read/38530985/chemical-peels-for-melasma-a-systematic-review
#16
JOURNAL ARTICLE
Rashmi Sarkar, Ridhima Lakhani
BACKGROUND: Melasma is a common chronic, relapsing pigmentary disorder that causes psychological impact. Chemical peels are a well-known therapeutic modality used for accelerating the treatment of melasma. OBJECTIVE: To review the published evidence on the efficacy and safety of chemical peels in the treatment of melasma. METHODS: A systematic review was done. A meta-analysis could not be done due to the heterogeneity of data. RESULT: The authors conducted a PubMed search and included prospective case series of more than 10 cases and randomized controlled trials (RCTs) that have studied the safety and/or efficacy of chemical peel in melasma...
March 26, 2024: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://read.qxmd.com/read/38448367/melasma-and-reflectance-confocal-microscopy-from-baseline-to-treatment-monitoring
#17
REVIEW
Stefania Guida, Caterina Longo, Riccardo Ronga, Giorgio Stabile, Antonio Podo Brunetti, Gianmarco D Bigotto, Claudio Conforti, Silvana Ciardo, Carmen Cantisani, Giovanni Paolino, Santo R Mercuri, Steven P Nisticò, Nicola Zerbinati, Franco Rongioletti, Giovanni Pellacani
Melasma is a frequent condition worldwide, and it represents one of the most challenging disorders to treat in cosmetic dermatology. One of the critical factors for treatment prognosis is the assessment of the depth and distribution of pigment within the hyperpigmented area. Nowadays, non-invasive skin imaging techniques, such as reflectance confocal microscopy (RCM), have been used to estimate pigment distribution and depth within different skin layers. This article aims to provide a systematic review of RCM applications in melasma, providing terminology and investigating characteristics of melasma at baseline and after medical and laser treatment...
March 6, 2024: International Journal of Dermatology
https://read.qxmd.com/read/38425108/biochemical-and-in-silico-studies-on-triazole-derivatives-as-tyrosinase-inhibitors-potential-treatment-of-hyperpigmentation-related-skin-disorders
#18
JOURNAL ARTICLE
Yusra Choudhary, Atia-Tul- Wahab, Humaira Zafar, Salman Siddiqui, Majid Khan, Khalid M Khan, Amer H Asseri, M Iqbal Choudhary, Atta-Ur- Rahman
INTRODUCTION: Tyrosinase is a versatile, glycosylated copper-containing oxidase enzyme that mainly catalyzes the biosynthesis of melanin in mammals. Its overexpression leads to the formation of excess melanin, resulting in hyperpigmentary skin disorders, such as dark spots, melasma, freckles, etc. Therefore, inhibition of tyrosinase is a therapeutic approach for the treatment of hyperpigmentation. METHOD: The current study focused on evaluating tyrosinase inhibitory activities of triazole derivatives 1-20, bearing different substituents on the phenyl ring...
February 29, 2024: Medicinal Chemistry
https://read.qxmd.com/read/38416809/does-systemic-metformin-have-a-role-in-treating-melasma
#19
JOURNAL ARTICLE
Sahar A Ismail, Ghada A Mohamed, Karima N Mohamedeen, Rehab S A Sotohy, Radwa M Bakr
BACKGROUND: Melasma is a common pigmentary condition that affects the patients' quality of life and all the prescribed treatment options till now are not satisfactory, especially in dark-skinned patients. OBJECTIVE: To evaluate the efficacy and safety of systemic metformin (1,000 mg and 500 mg) combined with trichloroacetic acid (TCA) peeling versus TCA alone in the treatment of melasma. PATIENTS AND METHODS: The study included 60 melasma patients divided into 3 groups: Group A received systemic metformin (1000 mg/d), Group B received systemic metformin (500 mg/d) and Group C received placebo...
April 1, 2024: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://read.qxmd.com/read/38414788/exposure-factors-in-the-occurrence-and-development-of-melasma-review
#20
REVIEW
Yijun Chen, Gautham Vellaichamy, Samantha L Schneider, Wei Kong, Zhichao Liu
Melasma is an acquired pigmentation disease that mainly involves the development of symmetrical yellow-brown facial patches. The incidence rate of the disease is increasing yearly. Therefore, actively studying the exposure factors that induce melasma could contribute to the prevention and treatment of this disease. In the present review, the possible exposure factors were summarized.
April 2024: Experimental and Therapeutic Medicine
keyword
keyword
12300
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.